$OTLK
Outlook Therapeutics, Inc.

2023 Q4 Form 10-K Financial Statement

#000155837023020000 Filed on December 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.794M $7.515M $26.67M
YoY Change -0.55% 50.36% 28.61%
% of Gross Profit
Research & Development $4.529M $4.944M $26.45M
YoY Change -54.07% -45.0% -37.51%
% of Gross Profit
Depreciation & Amortization $28.20K $14.19K $44.19K
YoY Change 161.6% -72.43% -72.99%
% of Gross Profit
Operating Expenses $4.529M $12.46M $26.45M
YoY Change -54.07% -10.93% -37.51%
Operating Profit -$10.32M -$53.13M
YoY Change -34.2% -15.77%
Interest Expense $191.2K $297.5K -$1.571M
YoY Change -107.88% -181.05% 2.26%
% of Operating Profit
Other Income/Expense, Net -$1.046M -$829.2K -$3.705M
YoY Change -3557.83% -7638.27% 788.51%
Pretax Income -$11.18M -$12.99M -$58.98M
YoY Change -40.1% -9.43% -10.7%
Income Tax $0.00 $2.800K
% Of Pretax Income
Net Earnings -$11.18M -$12.99M -$58.98M
YoY Change -40.1% -9.44% -10.7%
Net Earnings / Revenue
Basic Earnings Per Share -$0.04 -$0.24
Diluted Earnings Per Share -$0.04 -$0.05 -$0.24
COMMON SHARES
Basic Shares Outstanding 260.3M 260.2M 250.2M
Diluted Shares Outstanding 260.3M 250.2M

Balance Sheet

Concept 2023 Q4 2023 Q3 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.36M $23.39M $23.39M
YoY Change -80.21% 34.46% 34.46%
Cash & Equivalents $10.36M $23.39M $23.39M
Short-Term Investments
Other Short-Term Assets $10.03M $7.587M $7.587M
YoY Change 7.47% -25.05% -25.05%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $20.39M $30.98M $30.98M
YoY Change -66.94% 12.57% 12.57%
LONG-TERM ASSETS
Property, Plant & Equipment $14.96K $26.17K $26.17K
YoY Change -74.89% -62.81% -62.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $796.5K $793.9K $793.9K
YoY Change -3.62% -1.37% -1.37%
Other Assets $484.3K $501.3K $501.3K
YoY Change 283.04% 279.73% 279.72%
Total Long-Term Assets $1.296M $1.321M $1.321M
YoY Change 27.98% 31.18% 31.18%
TOTAL ASSETS
Total Short-Term Assets $20.39M $30.98M $30.98M
Total Long-Term Assets $1.296M $1.321M $1.321M
Total Assets $21.68M $32.30M $32.30M
YoY Change -65.41% 13.23% 13.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.480M $6.575M $6.575M
YoY Change -16.54% 88.3% 88.3%
Accrued Expenses $4.087M $2.746M $2.746M
YoY Change -54.73% -19.9% -20.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $36.55M $35.56M $35.56M
YoY Change 300930.31% 225.4% 225.4%
Total Short-Term Liabilities $45.97M $46.73M $46.73M
YoY Change 204.8% 136.86% 136.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $59.56K $6.220K $6.220K
YoY Change 121.58% -89.11% -89.11%
Total Long-Term Liabilities $59.56K $6.220K $6.220K
YoY Change -99.81% -89.87% -89.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $45.97M $46.73M $46.73M
Total Long-Term Liabilities $59.56K $6.220K $6.220K
Total Liabilities $46.03M $46.74M $46.74M
YoY Change -1.92% 136.16% 136.16%
SHAREHOLDERS EQUITY
Retained Earnings -$479.1M -$467.9M
YoY Change 12.04% 14.43%
Common Stock $454.8M $453.5M
YoY Change 2.57% 8.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$24.34M -$14.44M -$14.44M
YoY Change
Total Liabilities & Shareholders Equity $21.68M $32.30M $32.30M
YoY Change -65.41% 13.23% 13.23%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2023
OPERATING ACTIVITIES
Net Income -$11.18M -$12.99M -$58.98M
YoY Change -40.1% -9.44% -10.7%
Depreciation, Depletion And Amortization $28.20K $14.19K $44.19K
YoY Change 161.6% -72.43% -72.99%
Cash From Operating Activities -$13.03M -$12.74M -$42.97M
YoY Change 46.41% 24.32% -24.18%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $30.02M
YoY Change -51.81%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.183K 2.429M 48.97M
YoY Change -100.01% 49.35% -17.83%
NET CHANGE
Cash From Operating Activities -13.03M -12.74M -42.97M
Cash From Investing Activities
Cash From Financing Activities -3.183K 2.429M 48.97M
Net Change In Cash -13.04M -10.31M 5.995M
YoY Change -137.3% 19.6% 105.35%
FREE CASH FLOW
Cash From Operating Activities -$13.03M -$12.74M -$42.97M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001649989
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#WarrantsAndRightsOutstanding
CY2022Q3 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#WarrantsAndRightsOutstanding
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2022Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
260257517
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
227310572
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
250176633
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
212079472
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
250176633
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
212079472
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-37759
CY2023 dei Entity Registrant Name
EntityRegistrantName
OUTLOOK THERAPEUTICS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
38-3982704
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
485 Route 1 South
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Building F, Suite 320
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Iselin
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08852
CY2023 dei City Area Code
CityAreaCode
609
CY2023 dei Local Phone Number
LocalPhoneNumber
619-3990
CY2023 dei Security12b Title
Security12bTitle
Common Stock
CY2023 dei Trading Symbol
TradingSymbol
OTLK
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Public Float
EntityPublicFloat
179500000
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
260257517
CY2023 dei Auditor Firm
AuditorFirmId
185
CY2023 dei Auditor Name
AuditorName
KPMG LLP
CY2023 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23391982
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17396812
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7587216
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10123634
CY2023Q3 us-gaap Assets Current
AssetsCurrent
30979198
CY2022Q3 us-gaap Assets Current
AssetsCurrent
27520446
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26172
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
70360
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
793932
CY2022Q3 us-gaap Equity Method Investments
EquityMethodInvestments
804930
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
501299
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
132015
CY2023Q3 us-gaap Assets
Assets
32300601
CY2022Q3 us-gaap Assets
Assets
28527751
CY2023Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
35551000
CY2022Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
10915015
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
4267
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
11751
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
26995
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6574523
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3491485
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2745740
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3427900
CY2023Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1856629
CY2022Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1856629
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
46732159
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
19729775
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
4267
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
6219
CY2022Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
57138
CY2023Q3 us-gaap Liabilities
Liabilities
46738378
CY2022Q3 us-gaap Liabilities
Liabilities
19791180
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7300000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7300000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
425000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
425000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
260257517
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
227310572
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
2602574
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
2273105
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
450877835
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
415398984
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-467918186
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-408935518
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-14437777
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8736571
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32300601
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28527751
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26452942
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42330856
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26673440
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20739897
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-53126382
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-63070753
CY2023 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-10998
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-48730
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1559748
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1487456
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-577659
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1025402
CY2023 otlk Change In Fair Value Of Redemption Feature
ChangeInFairValueOfRedemptionFeature
3756000
CY2022 otlk Change In Fair Value Of Redemption Feature
ChangeInFairValueOfRedemptionFeature
882903
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-50919
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-465780
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-58979868
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66049464
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2800
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2800
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-58982668
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-66052264
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
250176633
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
212079472
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4607449
CY2022 otlk Stock Issue During Period Value In Connection With Exercise Of Warrants
StockIssueDuringPeriodValueInConnectionWithExerciseOfWarrants
188100
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17750
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
62264732
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
7710804
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-66052264
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8736571
CY2023 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
25000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30236301
CY2023 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5547019
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-58982668
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-14437777
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-58982668
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-66052264
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
44188
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
204694
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-577659
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1025402
CY2023 us-gaap Paid In Kind Interest
PaidInKindInterest
2529830
CY2022 us-gaap Paid In Kind Interest
PaidInKindInterest
1655340
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
5547019
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
7710804
CY2023 otlk Change In Fair Value Of Redemption Feature
ChangeInFairValueOfRedemptionFeature
3756000
CY2022 otlk Change In Fair Value Of Redemption Feature
ChangeInFairValueOfRedemptionFeature
882903
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-50919
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-465780
CY2023 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-10998
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-48730
CY2023 us-gaap Interest Paid
InterestPaid
1158609
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2616925
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3092811
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
208203
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-26995
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-42854
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3083038
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1295136
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-711661
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
156141
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42973398
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56674559
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30024213
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62307307
CY2023 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
30000000
CY2022 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
188100
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17750
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
11751
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
26464
CY2023 us-gaap Repayments Of Debt
RepaymentsOfDebt
10220000
CY2022 us-gaap Repayments Of Debt
RepaymentsOfDebt
12292646
CY2023 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
823894
CY2022 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
600000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48968568
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59594047
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5995170
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2919488
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17396812
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14477324
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23391982
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17396812
CY2023 us-gaap Interest Paid Net
InterestPaidNet
1160008
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1556691
CY2023 otlk Cloud Computing Implementation Costs In Accrued Expenses
CloudComputingImplementationCostsInAccruedExpenses
29500
CY2023 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
25000
CY2023 otlk Amortization Of Deferred Offering Cost
AmortizationOfDeferredOfferingCost
141600
CY2022 otlk Amortization Of Deferred Offering Cost
AmortizationOfDeferredOfferingCost
42575
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.     Organization and Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Description of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Outlook Therapeutics, Inc. (“Outlook” or the “Company”) was incorporated in New Jersey on January 5, 2010, started operations in July 2011, reincorporated in Delaware by merging with and into a Delaware corporation in October 2015 and changed its name to “Outlook Therapeutics, Inc.” in November 2018. The Company is a biopharmaceutical company focused on developing and commercializing ONS-5010, an ophthalmic formulation of bevacizumab for use in retinal indications. The Company is based in Iselin, New Jersey. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In fiscal year 2022, the Company submitted a Biologics License Application (“BLA”), and received confirmation from the U.S. Food and Drug Administration (“FDA”) that the BLA had been accepted for filing with a goal date of August 29, 2023 for a review decision by the FDA. On August 29, 2023, the Company received a Complete Response Letter (CRL) in which the FDA concluded it could not approve the BLA during this review cycle due to several chemical, manufacturing and control, or CMC, issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.  At subsequent Type A meetings with the FDA, the Company learned that the FDA requires the successful completion of an additional adequate and well-controlled clinical trial evaluating ONS-5010, as well as additional requested CMC data indicated in the CRL to approve ONS-5010 for use in wet age related macular degeneration (“wet AMD”). Additionally, the Company submitted a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA), which has been validated for review with an estimated decision date expected in early 2024.</p>
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-467918186
CY2023Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
36763381
CY2022Q3 us-gaap Notes And Loans Payable
NotesAndLoansPayable
10915015
CY2023Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
35551000
CY2022Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
10915015
CY2020Q3 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
3000000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p>
CY2021Q2 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
625000
CY2022Q2 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
750000
CY2023Q3 us-gaap Litigation Reserve Current
LitigationReserveCurrent
0
CY2021Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2023 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1399
CY2022 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3141
CY2023 otlk Finance Lease Cost
FinanceLeaseCost
1399
CY2022 otlk Finance Lease Cost
FinanceLeaseCost
3141
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
44867
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
919970
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1976252
CY2023Q3 otlk Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1234192
CY2022Q3 otlk Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
744154
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
165192
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
564423
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
426386
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
143071
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2745740
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3427900
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
35551000
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
11114518
CY2022Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
199503
CY2023Q3 us-gaap Notes And Loans Payable
NotesAndLoansPayable
35551000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
44867
CY2023 us-gaap Lease Cost
LeaseCost
46266
CY2022 us-gaap Lease Cost
LeaseCost
48008
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26172
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
70360
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
26995
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
4267
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
16018
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y7M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y3M18D
CY2022Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.130
CY2022Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.130
CY2023 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1399
CY2022 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
3141
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
27675
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
46652
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
11751
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
26464
CY2023Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
4383
CY2023Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
4383
CY2023Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
116
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
4267
CY2023 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
1
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.03
CY2023 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
136914
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
83266
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
325000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
425000000
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7328549
CY2022Q3 us-gaap Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
400360
CY2022Q3 otlk Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Unissued
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsUnissued
12.00
CY2022 otlk Stock Issued During Period Shares In Connection With Exercise Of Warrants
StockIssuedDuringPeriodSharesInConnectionWithExerciseOfWarrants
15675
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.00
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5547019
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7710804
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2800
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2800
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.073
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.071
CY2023 otlk Effective Income Tax Rate Reconciliation Deferred True Up Percent
EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent
0.001
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.007
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.013
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.013
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.035
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.290
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.321
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.005
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2023Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
92961718
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
83971779
CY2023Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
6531508
CY2023Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5066375
CY2022Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4331889
CY2022Q3 otlk Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
7588
CY2023Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11953956
CY2022Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11166153
CY2023Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
1562639
CY2022Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
2357309
CY2023Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1656239
CY2022Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
815310
CY2023Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
119732435
CY2022Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
102650028
CY2023Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
119725078
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
102630250
CY2023Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
7357
CY2022Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
19778
CY2023Q3 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
7357
CY2022Q3 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
19778
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
17100000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
21200000
CY2017Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1856629
CY2021Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1856629
CY2023 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2022 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2023Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1856629
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1856629

Files In Submission

Name View Source Status
0001558370-23-020000-index-headers.html Edgar Link pending
0001558370-23-020000-index.html Edgar Link pending
0001558370-23-020000.txt Edgar Link pending
0001558370-23-020000-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
otlk-20230930.xsd Edgar Link pending
otlk-20230930x10k.htm Edgar Link pending
otlk-20230930x10k006.jpg Edgar Link pending
otlk-20230930x10k007.jpg Edgar Link pending
otlk-20230930x10k008.jpg Edgar Link pending
otlk-20230930xex10d26.htm Edgar Link pending
otlk-20230930xex10d30.htm Edgar Link pending
otlk-20230930xex21d1.htm Edgar Link pending
otlk-20230930xex23d1.htm Edgar Link pending
otlk-20230930xex31d1.htm Edgar Link pending
otlk-20230930xex31d2.htm Edgar Link pending
otlk-20230930xex32d1.htm Edgar Link pending
otlk-20230930xex4d1.htm Edgar Link pending
otlk-20230930xex97.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
otlk-20230930_def.xml Edgar Link unprocessable
otlk-20230930_lab.xml Edgar Link unprocessable
otlk-20230930_pre.xml Edgar Link unprocessable
otlk-20230930x10k_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
otlk-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable